Sugi Predict

Sugi Predict / Compounds / SCHEMBL6670923

SCHEMBL6670923

SCHEMBL6670923

Clc1ccc(-c2cc(Cc3ccccc3)c3c(c2)[C@@H]2CNCC[C@@H]2O3)c(Cl)c1

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NMT1 P30419 2/20 0.36
▸ HTR2C P28335 1/20 0.35
▸ HTR2B P41595 1/20 0.35
▸ SLC6A2 P23975 2/20 0.35
▸ SLC6A4 P31645 2/20 0.35
▸ HTR2A P28223 2/20 0.33
▸ KCNH2 Q12809 2/20 0.33
▸ SLC6A3 Q01959 1/20 0.33
▸ MARS1 P56192 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ HIF1A Q16665 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ ACP1 P24666 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6647466 1.00 NMT1 (0.36) NMT1HTR2CHTR2BSLC6A2SLC6A4
SCHEMBL6670150 0.89 KCNH2 (0.33) HTR2CHTR2BSLC6A2SLC6A4HTR2A
SCHEMBL6669610 0.89 KCNH2 (0.33) HTR2CHTR2BSLC6A2SLC6A4HTR2A
SCHEMBL6642866 0.87 SLC6A2 (0.39) HTR2CHTR2BSLC6A2SLC6A4HTR2A
SCHEMBL6670894 0.87 SLC6A2 (0.39) HTR2CHTR2BSLC6A2SLC6A4HTR2A
SCHEMBL6668896 0.85 SLC6A2 (0.39) HTR2CHTR2BSLC6A2SLC6A4HTR2A
SCHEMBL6673865 0.85 SLC6A2 (0.39) HTR2CHTR2BSLC6A2SLC6A4HTR2A
SCHEMBL6669452 0.85 HTR2A (0.38) HTR2CSLC6A2SLC6A4HTR2AKCNH2
SCHEMBL6668683 0.85 HTR2A (0.38) HTR2CSLC6A2SLC6A4HTR2AKCNH2
SCHEMBL6669879 0.84 SLC6A2 (0.35) NMT1HTR2CHTR2BSLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6762191-B2 TREATING DISEASES FOR MODULATING OF 5-HT ACTIVITY, CENTRAL NERVOUS SYSTEM DISORDERS, ANXIETY, OBESITY, DEPRESSION, OR A STRESS-RELATED DISEASE PHARMACIA & UPJOHN COMPANY 2004-07-13 — — US claimed
US-20030050304-A1 Therapeutic compounds PHARMACIA & UPJOHN COMPANY 2003-03-13 — — US claimed
US-20040214815-A1 Therapeutic compounds PHARMACIA & UPJOHN COMPANY 2004-10-28 — — US disclosed
US-6762191-B2 TREATING DISEASES FOR MODULATING OF 5-HT ACTIVITY, CENTRAL NERVOUS SYSTEM DISORDERS, ANXIETY, OBESITY, DEPRESSION, OR A STRESS-RELATED DISEASE PHARMACIA & UPJOHN COMPANY 2004-07-13 — — US disclosed
EP-1404679-A2 (HETERO)ARYL SUBSTITUTED BENZOFURANS AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2004-04-07 — — EP disclosed
US-20030050304-A1 Therapeutic compounds PHARMACIA & UPJOHN COMPANY 2003-03-13 — — US disclosed
WO-2003004501-A2 (HETERO) ARYL SUBSTITUTED BENZOFURANS AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2003-01-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214815-A1 Therapeutic compounds HTR5A, HTR6, HTR1A NMT1 2364/4885HTR2C 14/4885HTR2B 21/4885
US-20030050304-A1 Therapeutic compounds HTR5A, HTR6, HTR1A NMT1 2364/4885HTR2C 14/4885HTR2B 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.